Zaloguj Zarejestruj się zadarmo

Telesis Bio Inc organizacji Rok IPO

Jaka jest wartość Rok IPO organizacji Telesis Bio Inc?

Wartość Rok IPO organizacji Telesis Bio Inc to 2017

Jaka jest definicja Rok IPO?

Pierwsza oferta publiczna jest rodzajem oferty publicznej, w której akcje spółki zazwyczaj sprzedawane są inwestorom instytucjonalnym, którzy z kolei sprzedają się ogółowi społeczeństwa, na giełdzie papierów wartościowych, po raz pierwszy.

Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.

Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.

The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.

Rok IPO firm w Health Care sektor na NASDAQ w porównaniu do Telesis Bio Inc

Czym się zajmuję organizacja Telesis Bio Inc?

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

Firmy z rok ipo podobne do Telesis Bio Inc